Subscribe
Home
Issues
2024
February 2024 - Vol 17 No 1
2023
December 2023 - Vol 16 No 6
October 2023 - Vol 16 No 5
August 2023 - Vol 16 No 4
June 2023 - Vol 16 No 3
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
Issue Archive
Special Issues
Supplements
Guide to New FDA Approvals
Categories
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
ONS 2023 - Multiple Myeloma: Wrap-Up
Web Exclusives
OFS Summit
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Audiocasts
Ask the Experts
Master Class Series
Resources
Quick Quiz
CE
A Systematic Review to Evaluate the Corresponding Toxicity and Side Effects of CDK4/6 Inhibitors in Advanced Breast Cancer
Breast Cancer
Web Exclusives
Although CDK4/6 inhibitors in the treatment of patients with hormone receptor–positive/
HER2
-negative advanced breast cancer improve progression-free survival, this therapeutic intervention is also associated with higher rates of adverse events.
Read More ›
Nurses Play a Critical Role in the Patient’s Health Throughout the Continuity of Care
Breast Cancer
Web Exclusives
To ensure the correct use of healthcare services, it is critical to invest in training nursing professionals who must educate patients on the timely recognition and management of complications.
Read More ›
Effect of Dose Modifications of Ribociclib and Endocrine Therapy for Patients with Estrogen Receptor–Positive/HER2-Negative Metastatic Breast Cancer
Breast Cancer
Web Exclusives
Study shows no compromise in treatment safety or efficacy associated with dose reduction of ribociclib.
Read More ›
Evaluating Efficacy and Safety Data on Palbociclib and Ribociclib Used in Routine Clinical Practice in India
Breast Cancer
Web Exclusives
Research suggests that, when used in routine clinical practice in first or subsequent lines of treatment, ribociclib and palbociclib resulted in toxicity and efficacy outcomes in agreement with pivotal trial expectations.
Read More ›
De-escalating Treatment to Endocrine Monotherapy in Patients with Advanced HR-Positive, HER2-Negative Breast Cancer After Initial Treatment with CDK4/6 Inhibitors
Breast Cancer
Web Exclusives
A small study suggests that in select patients with long-lasting disease stabilization, elective discontinuation of CDK4/6 inhibitors is feasible.
Read More ›
Assessing Outcomes and Socioeconomic and Racial Disparities Using Data from the National Cancer Institute’s SEER Program
Breast Cancer
Web Exclusives
A large retrospective cohort population-based study demonstrated a disproportionate elevation of breast cancer–specific and all-cause mortality among African American women.
Read More ›
Evaluating the Effectiveness and Toxicities Associated with Novel Oral Agents Palbociclib and Ribociclib to Understand the Influence of Regimen Changes on Disease Progression
Breast Cancer
Web Exclusives
For the treatment of patients with HR-positive/
HER2
-negative metastatic breast cancer, targeting CDK4/6 represents a novel, effective, and safe therapeutic approach in combination with hormone therapy.
Read More ›
A Comprehensive Literature Review of Available Real-World Evidence Evaluating CDK4/6 Inhibitors in Patients with HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
Breast Cancer
Web Exclusives
CDK4/6 inhibitors were associated with improved outcomes in HR-positive/
HER2
-negative advanced metastatic breast cancer.
Read More ›
In CDK4/6 Inhibitor and Endocrine Therapy–Resistant Breast Cancer, Co-Targeting CDK4/6 and AKT with Endocrine Therapy Prevents Progression
Breast Cancer
Web Exclusives
Study results suggest the potential of clinical development of estrogen receptor, CDK4/6, and AKT co-targeting strategies after progression on a CDK4/6 inhibitor and endocrine therapy combination, and in tumors showing high phospho-AKT levels.
Read More ›
Medicaid Expansion Significantly Improves Breast Reconstruction Disparities
By
William Ackerman
Breast Cancer
TON - October 2021 Vol 14, No 5
Medicaid expansion under the Affordable Care Act was associated with significant increases in breast reconstruction surgery among non-Hispanic black women and women with lower income and education levels, according to results of a study presented during the American Society of Breast Surgeons 22nd Annual Meeting.
Read More ›
Page 7 of 29
2
3
4
5
6
7
8
9
10
11
Home
Issues
2024
February 2024 - Vol 17 No 1
2023
December 2023 - Vol 16 No 6
October 2023 - Vol 16 No 5
August 2023 - Vol 16 No 4
June 2023 - Vol 16 No 3
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
Issue Archive
Special Issues
Supplements
Guide to New FDA Approvals
Categories
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
ONS 2023 - Multiple Myeloma: Wrap-Up
Web Exclusives
OFS Summit
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Audiocasts
Ask the Experts
Master Class Series
Resources
Quick Quiz
CE
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
TON
Print Edition
TON
Weekly e‑Newsletter
-- Please Select --
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
TON
's
Privacy Policy
, and
TON
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION